Robust HbA1c reductions through complementary insulin secretagogue pathways
JCI Insight 6 (3), e141851
Similarly, Novo Nordisk makes both insulin degludec (Tresiba) and semaglutide (Ozempic), plus a combination product called Xultophy that pairs insulin degludec with liraglutide
Early clinical trials in diabetic patients have indicated that GLP-1RAs treatment is associated with improvements in health-related quality of life and well-being compared with insulin and sulfonylureas
GH secretagogues can cause water retention, joint discomfort, or altered glucose metabolism at higher doses
Regional Segment Analysis of the GLP-1 Receptor Agonist Market North America (U.S., Canada, Mexico) Europe (Germany, France, U.K., Italy, Spain, Rest of Europe) Asia-Pacific (China, Japan, India, Rest of APAC) South America (Brazil and the Rest of South America) The Middle East and Africa (UAE, South Africa, Rest of MEA) North America influenced the market with the largest market share over the forecast period Get more details on this report - Request Free Sample PDF North America is influencing significant market growth during the forecast period due to the region's high prevalence of chronic illnesses such as diabetes and obesity, rising R&D investments for creating novel pharmaceuticals for treating diabetes and obesity, the presence of significant companies, and the well-developed healthcare infrastructure
